Uso de sacubitril/valsartán en pacientes hospitalizados en vida real

  1. López García, Juan Carlos
unter der Leitung von:
  1. F. Fernández Avilés Doktorvater/Doktormutter
  2. Manuel Martínez-Sellés Doktorvater

Universität der Verteidigung: Universidad Complutense de Madrid

Fecha de defensa: 02 von Februar von 2021

Gericht:
  1. Juan Tamargo Menéndez Präsident/in
  2. Juan Francisco Delgado Jiménez Sekretär/in
  3. José Luis Zamorano Gómez Vocal
  4. Esteban López de Sá Vocal
  5. Pedro Luis Sánchez Fernández Vocal

Art: Dissertation

Teseo: 155153 DIALNET lock_openDocta Complutense editor

Zusammenfassung

Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real-life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non-selected population, in Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in the Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF) trial, and in non-selected outpatients. Methods. Multicentre registry including 527 patients: 100 were started on sacubitril/valsartan during hospitalization (19.0%) and 427 as outpatients (81.0%). Clinical, analytical, and echocardiographic variables, previous therapies, and the starting dose of sacubitril/valsartan and its modification or suspension were collected throughout the follow-up...